Royce & Associates LP Acquires 227,600 Shares of Correvio Pharma Corp (CORV)

Royce & Associates LP raised its holdings in Correvio Pharma Corp (NASDAQ:CORV) by 89.3% during the 4th quarter, Holdings Channel reports. The firm owned 482,500 shares of the company’s stock after acquiring an additional 227,600 shares during the period. Royce & Associates LP’s holdings in Correvio Pharma were worth $1,201,000 as of its most recent filing with the SEC.

A number of other large investors have also bought and sold shares of the business. BlackRock Inc. purchased a new stake in Correvio Pharma in the fourth quarter valued at $39,000. Worth Venture Partners LLC purchased a new stake in Correvio Pharma in the third quarter valued at $173,000. Tamarack Advisers LP boosted its holdings in Correvio Pharma by 3.2% in the fourth quarter. Tamarack Advisers LP now owns 2,125,000 shares of the company’s stock valued at $5,291,000 after purchasing an additional 65,000 shares during the last quarter. Columbia Pacific Advisors LLC purchased a new stake in shares of Correvio Pharma during the 4th quarter worth about $251,000. Finally, Renaissance Technologies LLC boosted its stake in shares of Correvio Pharma by 22.1% during the 3rd quarter. Renaissance Technologies LLC now owns 739,248 shares of the company’s stock worth $2,972,000 after acquiring an additional 133,825 shares in the last quarter. 41.88% of the stock is currently owned by institutional investors.

CORV stock opened at $3.91 on Friday. The company has a debt-to-equity ratio of 4.02, a quick ratio of 3.46 and a current ratio of 4.05. Correvio Pharma Corp has a 52-week low of $1.48 and a 52-week high of $5.24. The stock has a market cap of $152.88 million, a PE ratio of -4.34 and a beta of 0.67.



Correvio Pharma (NASDAQ:CORV) last posted its earnings results on Wednesday, March 13th. The company reported ($0.18) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.19) by $0.01. Correvio Pharma had a negative net margin of 68.98% and a negative return on equity of 294.35%. The business had revenue of $8.95 million for the quarter, compared to analyst estimates of $8.40 million.

CORV has been the topic of several recent analyst reports. HC Wainwright reissued a “buy” rating and set a $10.50 target price on shares of Correvio Pharma in a research note on Monday, January 14th. B. Riley initiated coverage on shares of Correvio Pharma in a research note on Tuesday, December 4th. They set a “buy” rating and a $7.00 target price on the stock.

ILLEGAL ACTIVITY WARNING: “Royce & Associates LP Acquires 227,600 Shares of Correvio Pharma Corp (CORV)” was originally posted by Dakota Financial News and is owned by of Dakota Financial News. If you are viewing this report on another publication, it was stolen and republished in violation of U.S. and international trademark & copyright laws. The correct version of this report can be read at https://dakotafinancialnews.com/2019/03/15/royce-associates-lp-acquires-227600-shares-of-correvio-pharma-corp-corv.html.

Correvio Pharma Company Profile

Correvio Pharma Corp., a specialty pharmaceutical company, provides various products to meet the needs of acute care physicians and patients worldwide. It develops, acquires, and commercializes various brands for the in-hospital acute care market segment. The company's portfolio of marketed brands include Xydalba (dalbavancin hydrochloride) for the treatment of acute bacterial skin and skin structure infections; Zevtera/Mabelio (ceftobiprole medocaril sodium), a cephalosporin antibiotic for the treatment of community and hospital-acquired pneumonia; and Brinavess (vernakalant IV) for the rapid conversion of recent onset atrial fibrillation to sinus rhythm.

Further Reading: Certificate of Deposit (CD)

Want to see what other hedge funds are holding CORV? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Correvio Pharma Corp (NASDAQ:CORV).

Institutional Ownership by Quarter for Correvio Pharma (NASDAQ:CORV)

Receive News & Ratings for Correvio Pharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Correvio Pharma and related companies with MarketBeat.com's FREE daily email newsletter.